Estrogen receptor variants in normal human mammary tissue

Journal of the National Cancer Institute

Volumn 88, Issue 5, 1996, Pages 284-290

  Leygue, Etienne R ^a,b   Watson, Peter H ^b   Murphy, Leigh C ^a  

^a Dept of Biochem and Molec Biology ^*  (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; BREAST; BREAST NEOPLASMS; EXONS; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, ESTROGEN; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0029978698     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.5.284     Document Type: Article

References (26)

1. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
2. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987;51:941-51.
3. Beato M. Gene regulation by steroid hormones. Cell 1989;56:335-44.
4. Garcia T. Lehrer S, Bloomer WD. Schachter B. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol Endocrinol 1988;2:785-91.
5. Murphy LC, Dotzlaw H. Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 1989;3:687-93.
6. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991;51:105-9.
7. McGuire WL, Chamness GC, Fuqua SA. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol 1992;43: 243-7.
8. Wang Y, Miksicek RJ. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 1991;5:1707-15.
9. Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP. et al. Inhibition of estrogen receptor activity by a naturally occurring variant in human breast tumors. Cancer Res 1992;52:483-6.
10. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nowaz Z, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991;51:105-9.
11. Dotzlaw H, Alkhalaf M, Murphy LC. Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol 1992;6:773-85.
12. Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SA. Relationship of clone 4 estrogen receptor variant mRNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res 1995;1:155-9.
13. Fuqua SA, Allred DC, Elledge RM Kreig SL, Benedix MG. Nawaz. Z. et al. The ER-positive/PgR-negative breast cancer phenotype is nol associated with mutations within the DNA binding domain. Breast Cancer Res Treat 1993;26:191-202.
14. Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplaslic breast tissues and in MCF-7 cells. Cancer Res 1995; 55:2158-65.
15. Elston CW, Ellis IO. Pathological prognostic-factors in breast cancer. I. The value of histologicai grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
16. Nishida M. Kasahara K, Kaneko M, Iwasaki H. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet Gynecol 1985;37:1103-11.
17. Reddel RR, Alexander IE, Koga M, Shine J, Sutherland RL. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells. Cancer Res 1988;48:4340-7.
18. Watts CK, Handel ML, King RJ, Sutherland RL. Oestrogen receptor gene structure and function in breast cancer. J Steroid Biochem Mol Biol 1992;41:529-36.
19. Murphy LC, Dotzlaw H. Regulation of transforming growth factor alpha and transforming growth factor beta messenger ribonucteic acid abundance in T-47D. human breast cancer cells. Mol Endocrinol 1989;3:611-7.
20. Green S, Walter P, Kumar V, Krust A, Bomert JM, Argos P, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986;320:134-9.
21. Daffada AA, Johnston SR, Nicholls J, Dowsett M. Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymeruse chain reaction. J Mol Endocrinol 1994;13:265-73.
22. Daffada AA, Johnston SR, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 1995;55:288-93.
23. McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991;5:1571-7.
24. Sluyser M. Role of estrogen receptor variants in the development of hormone resistance in breast cancer. Clin Biochem 1992;25:407-14.
25. Horwitz KB. How do breast cancers become hormone resistant? J Steroid Biochem Mol Biol 1994;49:295-302.
26. Madsen MW, Reiter BE, Lykkesteldt AE. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line. MCF-7/TAMR-1 compared to the parental MCF-7 cell line. Mol Cell Endocrinol 1995;109:197-207.